颅咽管瘤中D2-40的表达及临床意义

Clinicopathological significance of D2-40 expression in craniopharyngioma

目的探讨D2-40在颅咽管瘤中的表达及与临床病理学特征的关系及意义。方法采用免疫组化法检测D2-40在126例颅咽管瘤中的表达,并复习相关文献。结果 D2-40在颅咽管瘤中的总阳性率为87.30%(110/126),其中(+)、()、()阳性率分别为44.44%(56/126)、37.30%(47/126)和5.56%(7/126)。造釉细胞型主要表达在中间层细胞,乳头瘤样型主要表达在基底层细胞,两型表达模式不同。随着肿瘤伴发炎症程度的加重,D2-40表达程度上调。在肿瘤浸润灶及侵袭前沿,D2-40常常高表达,表现为基底层细胞及中间层细胞同时弥漫表达,侵袭性颅咽管瘤中D2-40的表达程度高于非侵袭性颅咽管瘤。复发性颅咽管瘤中D2-40的表达程度高于非复发性颅咽管瘤。D2-40表达与患者性别、肿瘤组织学分型无明显相关性。结论 D2-40表达上调与颅咽管瘤的发生、发展相关,可能导致肿瘤细胞的侵袭能力增强,并可能与炎症相关机制有关。D2-40高表达可能是颅咽管瘤患者易复发的因素之一。

Purpose To investigate the expression pattern and clinicopathological significance of D2-40 in craniopharyngioma（ CP）. Methods Immunohistochemical method was used to assess D2-40 expression in 126 cases of craniopharyngioma. Statistic software was used to analyze the correlation between D2-40 expression and clinicopathological features. Results The overall positive rate of D2-40 expression in 126 craniopharyngioma was 87. 30%. The rate of ＋, and  were 44. 44%（ 56/126 ）,37. 30%（ 47/126 ）and 5. 56%（7/126）respectively. In adamantinomatous CPs,D2-40 expression was observed in epithelial components corresponding to the stratum intermedium,while in papillary CPs,it was immuno-positive in basal cells. With the increasing of the existence of inflamma-tion in tumor,D2-40 expression was up-regulated. Tumor cells were over-expressed for D2-40 in basal cells and stratum intermedium cells of the invasive frontier. D2-40 expression was higher in the invasive craniopharyngioma than in the non-invasive craniopharyngio-ma. In addition,D2-40 expression was higher in the recurrent craniopharyngioma than in the non-recurrent craniopharyngioma. There were no significant relationship between D2-40 expression and gender,and histological classification of tumors. Conclusions D2-40 expression is associated with the development of craniopharyngioma,which can lead to enhance the tumor cell invasion,and may be re-lated to inflammation-related mechanisms. D2-40 expression may be one of the recurrence factors in patients with craniopharyngioma.